Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome

被引:6
|
作者
Zhao, Ji-Meng [1 ]
Chen, Liu [1 ]
Zhou, Ci-Li [2 ]
Shi, Yin [1 ,2 ]
Li, Yu-Wei [1 ]
Shang, Hai-Xia [1 ]
Wu, Lu-Yi [1 ]
Bao, Chun-Hui [2 ]
Dou, Chuan-Zi [2 ]
Wu, Huan-Gan [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China
[2] Shanghai Inst Acupuncture Moxibust & Meridian, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
5-HT4; RECEPTOR; MAST-CELLS; SEROTONIN; DIARRHEA;
D O I
10.1155/2016/9410505
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Aim. To compare whether there is different effect between electroacupuncture (EA) and moxibustion (Mox) on visceral hypersensitivity (their analgesic effects) in constipation-predominant irritable bowel syndrome (C-IBS). Methods. EA at 1 mA and 3 mA and Mox at 43 degrees C and 46 degrees C were applied to the Shangjuxu (ST37, bilateral) acupoint in rats with C-IBS and normal rats. An abdominal withdrawal reflex (AWR) score was used to assess visceral hypersensitivity. Toluidine blue staining was used to assess mast cell (MC) activity in colon of rats. Immunochemistry was used to measure 5-HT and 5-HT4 receptor expression in the colon. Results. AWR scores in all EA (1 mA and 3 mA) and Mox (43 degrees C and 46 degrees C) treatment groups after colorectal distention (CRD) stimulation pressure of 20, 40, 60, and 80 mm Hg were significantly lower than those of the model (MC) group (P all < 0.01). The MC counts and degranulation rates in the colon of all EA and Mox treatment groups and the MC group were significantly higher than those of the NC group (P all < 0.01). MC degranulation rates in the colon of all EA and Mox treatment groups were lower than those of the MC group (P all < 0.05). 5-HT expression in colon of all EA and Mox treatment groups was significantly lower than that of the MC group (P all < 0.01), and 5-HT4R expression in colon of both EA groups was significantly higher than that of the MC group (P both < 0.01). Conclusion. EA andMox treatments may both ameliorate visceral hypersensitivity at different degree in rats with C-IBS, and EA treatment was better than Mox.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies
    Jadallah, Khaled A.
    Kullab, Susan M.
    Sanders, David S.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 8898 - 8909
  • [42] Autonomic nervous system activity in constipation-predominant irritable bowel syndrome patients
    Mazur, Marcel
    Furgala, Agata
    Jablonski, Konrad
    Mach, Tomasz
    Thor, Piotr
    MEDICAL SCIENCE MONITOR, 2012, 18 (08): : CR493 - CR499
  • [43] Clinical and anorectal manometry profile of patients with functional constipation and constipation-predominant irritable bowel syndrome
    Goyal, Omesh
    Bansal, Monika
    Sood, Ajit
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2019, 38 (03) : 211 - 219
  • [44] Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome: The Puzzle Is Yet to Be Solved
    Sanjeev Sachdeva
    Raghuram Kondala
    Amol Sonyabapu Dahale
    Amarender Singh Puri
    Digestive Diseases and Sciences, 2014, 59 : 2836 - 2837
  • [45] A 54-year-old woman with constipation-predominant irritable bowel syndrome
    Lembo, AJ
    Reynolds
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (08): : 925 - 933
  • [46] Colonoscopic features of functional constipation and constipation-predominant irritable bowel syndrome (IBS-C)
    Takeshi, M.
    Hidekazu, S.
    Toshifumi, H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 : 21 - 22
  • [47] The management of constipation-related functional gastrointestinal disorder (constipation-predominant irritable bowel syndrome)
    Amal F. Radwan
    Nagwa R. Ahmed
    Eman A. Sultan
    The Egyptian Journal of Internal Medicine, 2015, 27 (4) : 127 - 132
  • [48] Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
    Prather, CM
    Camilleri, M
    Zinsmeister, AR
    McKinzie, S
    Thomforde, G
    GASTROENTEROLOGY, 2000, 118 (03) : 463 - 468
  • [49] Effect of bifidogenic growth stimulator on patients with constipation-predominant irritable bowel syndrome
    Amano, Tomofumi
    Ariga, Hajime
    Yamato, Shigeru
    GASTROENTEROLOGY, 2008, 134 (04) : A552 - A552
  • [50] Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
    Vazquez-Roque, Maria I.
    Bouras, Ernest P.
    ADVANCES IN THERAPY, 2013, 30 (03) : 203 - 211